Emerging therapies for melanoma

Expert Review of Anticancer Therapy

Volumn 8, Issue 4, 2008, Pages 553-560

  Katipamula, Rajini ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis inhibitors; Chemotherapy; Emerging therapies; Immunotherapy; Melanoma; Targeted therapies

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENDRITIC CELL VACCINE; DEXAMETHASONE; EVEROLIMUS; FLUDARABINE; IPILIMUMAB; MELANOMA VACCINE; OBLIMERSEN; PACLITAXEL; PEPTIDE VACCINE; PLACEBO; PREDNISOLONE ACETATE; RAF KINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; SORAFENIB; STA 4783; STEROID; TEMOZOLOMIDE; TICILIMUMAB; UNINDEXED DRUG; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; PROTEIN KINASE INHIBITOR;

ADOPTIVE TRANSFER; AMNESIA; ANEMIA; ARTHRITIS; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BLURRED VISION; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTEROCOLITIS; FATIGUE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOPHYSITIS; LEUKOPENIA; LIBIDO DISORDER; LUNG INFILTRATE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOCYTE TRANSFER; MELANOMA; MONOTHERAPY; NAUSEA; NEPHRITIS; NEUTROPENIA; PROTEINURIA; REVIEW; SENTINEL LYMPH NODE BIOPSY; THROMBOCYTOPENIA; TOXIC HEPATITIS; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; UVEITIS; VITILIGO; ADJUVANT CHEMOTHERAPY; IMMUNOLOGY; IMMUNOTHERAPY; METASTASIS; PATHOLOGY; SKIN TUMOR;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MELANOMA; PROTEIN KINASE INHIBITORS; SKIN NEOPLASMS;

EID: 43049167320     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.4.553     Document Type: Review

References (41)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19(16), 3635-3648 (2001).
3. Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355(13), 1307-1317 (2006).
4. Carlson GW, Murray DR, Hestley A et al. Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it? Ann. Surg. Oncol. 10(4), 408-415 (2003).
5. Ra JH, McMasters KM, Spitz FR. Should all melanoma patients undergo sentinel lymph node biopsy? Curr. Opin. Oncol. 18(2), 185-188 (2006).
6. Ranieri JM, Wagner JD, Wenck S, Johnson CS, Coleman JJ 3rd. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann. Surg. Oncol. 13(7), 927-932 (2006).
7. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116 (1999).
8. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7-17 (1996).
9. Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 23(35), 8968-8977 (2005).
10. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad Sci. USA 100(14), 8372-8377 (2003).
11. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12(12), 1005-1016 (2005).
12. Sanderson K, Scotland R, Lee P et al. Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23(4), 741-750 (2005).
13. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 25(Suppl. 2), B4-B16 (2007).
14. Fay JW, Palucka AK, Paczesny S et al. Long-term survival in patients with metastatic melanoma vaccinated with melanoma-antigen loaded dendritic cells. J. Clin. Oncol. 25(18 Suppl.), 8547 (2007).
15. Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin. Cancer Res. 12(7 Pt 2), S2331-S2336 (2006).
16. Morton DL, Mozzillo N, Thompson JF et al. An international, randomized, Phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. MMAIT Clinical Trials Group. J. Clin. Oncol. 25(18 Suppl.), 8508 (2007).
17. Wheatley K, Hancock B, Gore M et al, on behalf of International Malignant Melanoma Collaborative Group. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J. Clin. Oncol. 25(18 Suppl.), 8526 (2007).
18. Moschos SJ, Edington HD, Land SR et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon α-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J. Clin. Oncol. 24(19), 3164-3171 (2006).
19. Spitler LE, Grossbard ML, Ernstoff MS et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 18(8), 1614-1621 (2000).
20. Patel TA, Baweja M, Maples W, Markovic SN. Granulocyte macrophage colony stimulating factor as adjuvant therapy for resected stage III/IV melanoma: retrospective review of a single institutional experience. J. Clin. Oncol. 25(18 Suppl.), 19002 (2007).
21. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14639-14645 (2004).
22. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006).
23. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002).
24. McDermott DF Sosman J, Cranmer FL et al. Randomized Phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma. J. Clin. Oncol. 25(18 Suppl.), 8511 (2007).
25. Flaherty KT Brose M, Schluchter L et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrate preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 22(14 Suppi.) 7507 (2004).
26. Agarwala S, Keilholz U, Hauschild A et al. Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J. Clin. Oncol. 25(18 Suppl.), 8510 (2007).
27. Rao R, Allred, JB, Markovic, SN et al. Results of NCCTG Phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma. J. Clin. Oncol. 25(18 Suppl.), 8530 (2007).
28. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24(29), 4738-4745 (2006).
29. Tas F, Duranyildiz D, Oguz H et al. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 16(5), 405-411 (2006).
30. Perez D, Suman V, Amatruda T et al. Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. J. Clin. Oncol. 25(18 Suppl.), 8560 (2007).
31. Ohm JE, Gabrilovich DI, Sempowski GD et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101 (12), 4878-4886 (2003).
32. Kaufmann R, Spieth K, Leiter U et al. Temozolomide in combination with interferon-α versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, Phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J. Clin. Oncol. 23(35), 9001-9007 (2005).
33. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am. J. Clin. Oncol. 25(3), 283-286 (2002).
34. Zimpfer-Rechner C, Hofmann U, Figl R et al. Randomized Phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 13(5), 531-536 (2003).
35. Rao RD, Holtan SG, Ingle JN et al. Combination of paditaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106(2), 375-382 (2006).
36. Salgia R, Berkenblit A, Dezube B, Dahl TA, STA-4783, a novel HSP inducer, enhances paclitaxel activity - preclinical to clinical modeling. J. Clin. Oncol. 22(14 Suppl.), 3124 (2004).
37. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24(15), 2283-2289 (2006).
38. Blansfield JA, Beck KE, Tran K et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 28(6), 593-598 (2005).
39. Robinson MR, Chan CC, Yang JC et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J. Immunother. 27(6), 478-479 (2004).
40. Varker KA, Biber JE, Kefauver C et al. A randomized Phase II trial of bevacizumab with or without daily low-dose Interferon α-2b in metastatic malignant melanoma. Ann. Surg. Oncol. 14(8), 2367-2376 (2007).
41. Egen JG, Kuhn MS, Allison JP, CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3(7), 611-618 (2002).